Immunomedics of Morris Plains, NJ, last week announced that ithas received clearance from the European Commission to marketits CEA-Scan colorectal cancer imaging agent in the 15 countriesof the European Union. The monoclonal-antibody-based agent
Immunomedics of Morris Plains, NJ, last week announced that it
has received clearance from the European Commission to market
its CEA-Scan colorectal cancer imaging agent in the 15 countries
of the European Union. The monoclonal-antibody-based agent received
U.S. clearance in June (SCAN 7/17/96). Mallinckrodt Medical of
St. Louis has marketing rights to CEA-Scan in both the U.S. and
Europe.